Actively Recruiting
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Led by Hutchmed · Updated on 2025-12-30
502
Participants Needed
2
Research Sites
212 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer
CONDITIONS
Official Title
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand and voluntarily sign informed consent and willing to follow study procedures
- Age between 18 and 75 years inclusive
- Confirmed pancreatic cancer by histology or cytology
- Stage IV metastatic pancreatic cancer
- No prior systemic first-line anti-tumor treatment for metastatic pancreatic cancer
- At least one measurable lesion per RECIST 1.1 criteria
- ECOG Performance Status score of 0 or 1
- Expected survival time of at least 12 weeks
You will not qualify if you...
- Received systemic anti-tumor therapy within 2 weeks before first dose
- Other malignancies within the past 5 years
- Major surgery within 60 days before first dose
- Surgery or invasive treatment within 4 weeks before first dose
- Palliative radiotherapy within 1 week or radical radiotherapy within 4 weeks before first dose
- Known allergy to surufatinib, camrelizumab, nab-paclitaxel, gemcitabine, or their components
- Use of CYP3A inducers or inhibitors within 2 weeks or 5 half-lives before first dose
- Use of immunosuppressive drugs within 4 weeks before first dose
- Known clinically significant liver disease or active hepatitis
- Uncontrolled hypertension despite medication
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China, 210000
Not Yet Recruiting
2
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China, 300000
Actively Recruiting
Research Team
P
Panfeng Tan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here